Abstract
Nonserious infections (NSIE) as colds, flu syndromes, and urinary tract infection, are the most common infections seen in patients with immune mediated inflammatory diseases. Yet, little is known about the impact of immunosuppression, particularly with tumor necrosis factor inhibitors (TNFi), on these infections. A systemic review of large, randomized controlled trials was conducted to identify incidence, types, and outcomes of NSIE associated with the most commonly prescribed TNFi: adalimumab, etanercept, and infliximab.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 707-725 |
| Number of pages | 19 |
| Journal | Rheumatic Disease Clinics of North America |
| Volume | 38 |
| Issue number | 4 |
| DOIs | |
| State | Published - Nov 1 2012 |
| Externally published | Yes |
Keywords
- Adalimumab
- Anti-TNF
- Etanercept
- Infliximab
- Nonserious infections
- Rheumatoid arthritis
- Safety
ASJC Scopus subject areas
- Rheumatology
Fingerprint Dive into the research topics of 'Nonserious Infections. Should There Be Cause for Serious Concerns?'. Together they form a unique fingerprint.
Cite this
Dao, K. H., Herbert, M., Habal, N., & Cush, J. J. (2012). Nonserious Infections. Should There Be Cause for Serious Concerns? Rheumatic Disease Clinics of North America, 38(4), 707-725. https://doi.org/10.1016/j.rdc.2012.08.016